-
Something wrong with this record ?
Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A₃ receptor agonist on hematopoiesis in sublethally γ-irradiated mice
M. Hofer, M. Pospíšil, L. Dušek, Z. Hoferová, L. Weiterová
Biomedicine & pharmacotherapy.
2011 ;
65 (6) :
427-431.
[pub] 20110612
Language English Country France
Document type Journal Article, Research Support, Non-U.S. Gov't
Persistent link
https://www.medvik.cz/link/bmc12022133
- MeSH
- Adenosine administration & dosage analogs & derivatives therapeutic use MeSH
- Adenosine A3 Receptor Agonists administration & dosage therapeutic use MeSH
- Whole-Body Irradiation MeSH
- Erythroid Precursor Cells drug effects radiation effects MeSH
- Radiation Injuries, Experimental blood drug therapy pathology MeSH
- Granulocyte Colony-Stimulating Factor blood MeSH
- Hematinics administration & dosage therapeutic use MeSH
- Hematopoietic Stem Cells drug effects radiation effects MeSH
- Hematopoiesis drug effects radiation effects MeSH
- Cyclooxygenase 2 Inhibitors administration & dosage therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Crosses, Genetic MeSH
- Mice, Inbred CBA MeSH
- Mice MeSH
- Cell Count MeSH
- Granulocyte Precursor Cells drug effects radiation effects MeSH
- Thiazines administration & dosage therapeutic use MeSH
- Thiazoles administration & dosage therapeutic use MeSH
- Gamma Rays adverse effects MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Mouse hematopoiesis, suppressed by a sublethal dose of ionizing radiation, was the target for combined therapy with a cyclooxygenase-2 (COX-2) inhibitor meloxicam and an adenosine A₃ receptor agonist IB-MECA. The drugs were administered in an early postirradiation treatment regimen: meloxicam was given in a single dose 1hour after irradiation, IB-MECA in two doses 24 and 48hours after irradiation. Treatment-induced changes in several compartments of hematopoietic progenitor and precursor cells of the bone marrow were evaluated on day 3 after irradiation. Values of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (GM-CFC and BFU-E, respectively), as well as those of proliferative granulocytic cells were found to be significantly higher in the mice treated with the drug combination in comparison to irradiated controls and attained the highest increase factors of 1.6, 1.6, and 2.6, respectively. The study emphasizes the significance of the combined treatment of suppressed hematopoiesis with more agents. Mechanisms of the action of the individual compounds of the studied drug combination and of their joint operation are discussed.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022133
- 003
- CZ-PrNML
- 005
- 20151124115847.0
- 007
- ta
- 008
- 120806s2011 fr f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2011.04.033 $2 doi
- 035 __
- $a (PubMed)21719245
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Hofer, Michal $u Research Group of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Brno, Czech Republic $7 xx0074123
- 245 10
- $a Inhibition of cyclooxygenase-2 promotes the stimulatory action of adenosine A₃ receptor agonist on hematopoiesis in sublethally γ-irradiated mice / $c M. Hofer, M. Pospíšil, L. Dušek, Z. Hoferová, L. Weiterová
- 520 9_
- $a Mouse hematopoiesis, suppressed by a sublethal dose of ionizing radiation, was the target for combined therapy with a cyclooxygenase-2 (COX-2) inhibitor meloxicam and an adenosine A₃ receptor agonist IB-MECA. The drugs were administered in an early postirradiation treatment regimen: meloxicam was given in a single dose 1hour after irradiation, IB-MECA in two doses 24 and 48hours after irradiation. Treatment-induced changes in several compartments of hematopoietic progenitor and precursor cells of the bone marrow were evaluated on day 3 after irradiation. Values of hematopoietic progenitor cells for granulocytes/macrophages and erythrocytes (GM-CFC and BFU-E, respectively), as well as those of proliferative granulocytic cells were found to be significantly higher in the mice treated with the drug combination in comparison to irradiated controls and attained the highest increase factors of 1.6, 1.6, and 2.6, respectively. The study emphasizes the significance of the combined treatment of suppressed hematopoiesis with more agents. Mechanisms of the action of the individual compounds of the studied drug combination and of their joint operation are discussed.
- 650 _2
- $a adenosin $x aplikace a dávkování $x analogy a deriváty $x terapeutické užití $7 D000241
- 650 _2
- $a agonisté adenosinového receptoru A3 $x aplikace a dávkování $x terapeutické užití $7 D058909
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a počet buněk $7 D002452
- 650 _2
- $a křížení genetické $7 D003433
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x aplikace a dávkování $x terapeutické užití $7 D052246
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a erytroidní prekurzorové buňky $x účinky léků $x účinky záření $7 D015672
- 650 _2
- $a záření gama $x škodlivé účinky $7 D005720
- 650 _2
- $a faktor stimulující kolonie granulocytů $x krev $7 D016179
- 650 _2
- $a prekurzorové buňky granulocytů $x účinky léků $x účinky záření $7 D042381
- 650 _2
- $a hematinika $x aplikace a dávkování $x terapeutické užití $7 D006397
- 650 _2
- $a hematopoéza $x účinky léků $x účinky záření $7 D006410
- 650 _2
- $a hematopoetické kmenové buňky $x účinky léků $x účinky záření $7 D006412
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední CBA $7 D008808
- 650 _2
- $a experimentální radiační poranění $x krev $x farmakoterapie $x patologie $7 D011833
- 650 _2
- $a thiaziny $x aplikace a dávkování $x terapeutické užití $7 D013843
- 650 _2
- $a thiazoly $x aplikace a dávkování $x terapeutické užití $7 D013844
- 650 _2
- $a celotělové ozáření $7 D014916
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pospíšil, Milan, $d 1929- $7 jk01100711 $u Research Group of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Dušek, Ladislav, $d 1967- $7 mzk2003181727 $u Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Hoferová, Zuzana $7 xx0074124 $u Research Group of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Weiterová, Lenka $7 xx0075192 $u Research Group of Experimental Hematology, Institute of Biophysics, v.v.i., Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomédecine & pharmacothérapie $x 1950-6007 $g Roč. 65, č. 6 (2011), s. 427-431
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21719245 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20151124115915 $b ABA008
- 999 __
- $a ok $b bmc $g 944046 $s 779430
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 65 $c 6 $d 427-431 $e 20110612 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $b NLK111 $a Pubmed-20120806/12/01
